Sign in

Trial result ·

A phase III double-blind, placebo-controlled, randomized withdrawal trial of 5‑aminolevulinic acid hydrochloride with sodium ferrous citrate for efficacy and safety in patients diagnosed as Leigh syndrome.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

This study tested a drug called SPP-004 in people with Leigh syndrome. SPP-004 combines 5-aminolevulinic acid with sodium ferrous citrate. All the people had signs of problems in the brain and nerves. First, 54 people took SPP-004 for 24 weeks and knew what they took. Then 28 people who had improved went on to a second stage. By chance, they got either SPP-004 or a dummy drug for 48 weeks. Neither they nor the study team knew who got which.

What they found

The main test was who stopped because the drug did not help enough. Fewer people stopped in the SPP-004 group than in the dummy drug group. The authors report that most people on SPP-004 kept their gains. All side effects linked to the drug were mild. There were no clear differences in harms between the groups.

What it means for patients

The authors suggest that SPP-004 is safe for people with Leigh syndrome. They say it may help people who responded to it at first. In these people, it may help keep up the gains they made.

Why it is not certain yet

The second stage was small. Only 13 people on SPP-004 and 14 on the dummy drug were counted. Only people who improved at first went on to the second stage. So the results may not apply to people who did not respond. In the first stage, there was no dummy drug group to compare with.

Source

A phase III double-blind, placebo-controlled, randomized withdrawal trial of 5‑aminolevulinic acid hydrochloride with sodium ferrous citrate for efficacy and safety in patients diagnosed as Leigh syndrome.

PubMed · PMID 42467686

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Mitochondrial disease publications